Replies to post #142486 on Biotech Values

[exwannabe]

Dr. Ron Garren says that CLDX will try to do a small, single-arm study with PFS as the primary endpoint under "accelerated approval."

Wow.

Does not the FDA clearly not consider time based endpoints in single arm studies for registrational purposes (even accelerated)?

Who is smoking what?